about
High-resolution functional mapping of the venezuelan equine encephalitis virus genome by insertional mutagenesis and massively parallel sequencingThottapalayam Virus, a Prototype Shrewborne HantavirusDiscovery of a novel compound with anti-venezuelan equine encephalitis virus activity that targets the nonstructural protein 2The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infectionThe role of particle-mediated DNA vaccines in biodefense preparedness.Vaccines for hantaviruses.A chronological review of experimental infection studies of the role of wild animals and livestock in the maintenance and transmission of Crimean-Congo hemorrhagic fever virusMeeting report: Tenth International Conference on Hantaviruses.Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular EntryGeneration of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain.Cassette vectors for conversion of Fab fragments into full-length human IgG1 monoclonal antibodies by expression in stably transformed insect cells.Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine.A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skinCellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins.A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge.Current strategic thinking for the development of a trivalent alphavirus vaccine for human useRecommendations for publication of viral genetic data and sample access for novel viruses and strainsComparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.DNA vaccines for biodefense.Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses.Endothelial cell permeability during hantavirus infection involves factor XII-dependent increased activation of the kallikrein-kinin system.A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses.A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.DNA vaccines for flaviviruses.Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccinesHuman Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation.Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein.Ebola virus VP30 is an RNA binding proteinCodon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challengesLipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses.Military vaccines in today's environmentPreclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases.IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus.Hantaan virus nucleocapsid protein binds to importin alpha proteins and inhibits tumor necrosis factor alpha-induced activation of nuclear factor kappa B.Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against HantavirusNuclear relocalization of polyadenylate binding protein during rift valley fever virus infection involves expression of the NSs geneProgress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.Biosafety standards for working with Crimean-Congo hemorrhagic fever virus.
P50
Q27313085-48EE1297-C518-4EE5-8B8A-E7A6122337F0Q27485434-FC28E0B6-C720-4639-853A-2E5DFEDEC660Q28540101-26AA1497-6DD5-47F2-88FC-615EC3383F00Q28546865-6FED7A5C-FE90-4707-82ED-1CC636AED3ABQ30150814-73111AD1-CDED-4E81-8F2F-45E7151A85EDQ30227484-51895C71-CD0B-424B-BD2C-D22147F3C31CQ30244052-75920AE1-0EAA-4ACB-967B-B0CFF79082DBQ30248373-77DB17AA-BA40-40A7-ADDE-80A1B46021E3Q30276615-8195CF53-9A4A-42BD-8C58-BC39DD0E1647Q30870545-0A1ED328-4A22-4B1D-8D86-3D5CF2C1B14EQ31155873-CF3A9D3B-A2CA-4FE5-887D-7B79FAD0629CQ33437280-AD61A23D-3760-4DF1-8EB8-379EC2E9D05FQ33723334-B997EB11-8F50-4DF3-8043-833BEAE85631Q33780460-4C0BAFA8-894D-40A9-9F83-29D9951711B2Q34033322-E8DE785E-4184-4861-BEAB-7E43E75C41B6Q34138417-1F86A79B-B78E-44CD-8DE1-7796697FAC6DQ34149781-4BD403E6-76A3-4717-8818-DD8E2A2B1B5AQ34223117-975B4EF8-82BF-46A3-9FE9-0B4BD2D8F841Q34614260-CDBBFA4D-E2CB-4200-8CFF-A046B2DCFA6FQ34725292-2CA6DA86-6EF6-491F-81B4-4C856434F538Q34845482-A442B3A0-02EA-4B8C-8AA9-352F848767B9Q34999859-74C9AF49-0778-4D4F-84B0-7BD6B73B8FBDQ35066196-91695303-DB01-4C3A-888B-E0DB718F7DE0Q35625045-D5285C43-EF5D-467A-983A-E4BD3668F7BFQ35635459-F6B70C84-0338-40DF-9623-862F4CA7C16DQ35793699-A38999F3-FCD1-40BD-B45B-55EB1A1FFE3FQ35826698-2F5A3807-822D-49A3-B9C0-0109AA9A7E66Q35857234-27F8CB5A-2A61-44EC-BC23-E68124964B0BQ35947850-0340CA7B-21CA-4202-994F-9F0828EF0DF1Q36255716-49856870-2702-467B-9FD5-299716C36B12Q36370336-F586175E-5119-458B-8149-6EF2A188C835Q36552915-B75C8E6A-DE05-46D3-ABD5-4A08291885E4Q36602269-17086A26-38EE-4DEB-B930-D857B84EBF4AQ37036679-71D80D86-6074-42E7-AC2D-33ABDBB9D064Q37051589-64C4B0AB-A11F-4374-B397-3C39581589DCQ37216441-47501D68-3A43-41A4-B360-AD7514515B49Q37252699-61C1468E-8075-47DE-A321-7DB05C23C53DQ37934045-17E6D301-DA2E-4752-ADF4-9BD8A6A51F1FQ38730774-F68D0C6C-7871-4084-A580-AA582922396FQ39584617-215F7CE3-9AF7-4881-93E6-E7844D403E56
P50
name
Connie S Schmaljohn
@en
type
label
Connie S Schmaljohn
@en
prefLabel
Connie S Schmaljohn
@en